Company intelligence / Profile preview

Nonagen Bioscience

Los Angeles, California, United Statesnonagen.com ↗

Ownership: Private
Development stage: Other

Overview

Nonagen Bioscience develops advanced diagnostic tests focused on oncology. Its lead product, Oncuria®, a multiplex immunoassay using urine samples to detect and monitor bladder cancer, has received FDA Breakthrough Device Designation. Pivotal clinical trials are nearing completion as of mid–2025. The company’s pipeline includes additional diagnostics targeting breast/prostate cancers and liver fibrosis. Commercialization partnerships are underway.

Therapeutic areas: GastroenterologyOncology
Modalities: Diagnostic test (Multiplex immunoassay)Multianalyte assay with algorithmic analysis (MAAA)Protein biomarker-based diagnostics
Industry: Protein Biomarker Diagnostics

Partnerships

Peregrine Market Access – contract commercialization partner for US launch of Oncuria® suite under a multiyear agreement.

Beyond the preview

Go deeper on Nonagen Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nonagen Bioscience.